Explore the vast range of titles available.

Between 2008 and 2019, 58,914 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) throughout China. In this report, we focus on 2019 data and describe current trends in HSCT in China. There was continued growth in transplant activity in China, with a rapid increase in haploidentical HSCT. In 2019, a total of 12,323 cases of HSCT were reported from 149 transplant teams, 78% (9597 cases) were allogeneic HSCTs. Haploidentical donor (HID) HSCT accounted for 60% (5771 cases) of allogeneic HSCT. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (AML) (37%) and acute lymphoblastic leukemia (ALL) (24%), and the largest proportion of non-malignant diseases comprised aplastic anemia (AA) (13%). Multiple stem cell source composed 70% of HID and 28% of MSD, which was typical in China. The BuCy based regimen (59%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu based regimen (23%) and TBI-based regimen (12%). This survey clearly shows comprehensive information about the current state and recent trends for HSCT in China. Further efforts should be made to obtain detailed information.

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.

This paper provides a comprehensive review of the literature related to seaport decarbonisation by combining the academic literature with case studies, industrial reports, newsletters, and domain knowledge. Through the literature review, the emission sources at seaports are categorised according to different criteria for better understanding. One of the criteria is the geographic location, which divides the emission sources into four categories. For each emission source category, the emission reduction measures in the literature are categorised into six structured categories including operational measures, technical measures, fuel and energy measures, infrastructural measures, digitalisation measures, and policy and collaboration measures. The first three categories have a direct impact on emission reductions, whereas the last three categories tend to support and facilitate the development and implementation of the first three categories. Representative case studies are selected from the UK ports to discuss their decarbonisation practices and pathways to net zero. We then propose a generic time-phased roadmap for port decarbonisation towards net zero, which divides the solution measures in each category into three phases to show their progressive processes. We explain the dependence relationships of the solution measures in the roadmap and discuss the challenges and opportunities in the implementation of the roadmap. This paper could offer strategic guidelines to port-associated stakeholders to implement emission reduction strategies and transition to net zero from the system perspective.

HighlightsThe rGH@FeNi/epoxy electromagnetic interference (EMI) shielding composites with regular 3D honeycomb structures were prepared by sacrificial template, freeze-drying and vacuum-assisted impregnation of epoxy resin.The construction of 3D honeycomb structure and electromagnetic synergistic effect significantly increase the EMI shielding effectiveness and reduce the secondary contamination.The rGH@FeNi/epoxy composites possess excellent thermal stability and mechanical properties.With the rapid development of fifth-generation mobile communication technology and wearable electronic devices, electromagnetic interference and radiation pollution caused by electromagnetic waves have attracted worldwide attention. Therefore, the design and development of highly efficient EMI shielding materials are of great importance. In this work, the three-dimensional graphene oxide (GO) with regular honeycomb structure (GH) is firstly constructed by sacrificial template and freeze-drying methods. Then, the amino functionalized FeNi alloy particles (f-FeNi) are loaded on the GH skeleton followed by in-situ reduction to prepare rGH@FeNi aerogel. Finally, the rGH@FeNi/epoxy EMI shielding composites with regular honeycomb structure is obtained by vacuum-assisted impregnation of epoxy resin. Benefitting from the construction of regular honeycomb structure and electromagnetic synergistic effect, the rGH@FeNi/epoxy composites with a low rGH@FeNi mass fraction of 2.1 wt% (rGH and f-FeNi are 1.2 and 0.9 wt%, respectively) exhibit a high EMI shielding effectiveness (EMI SE) of 46 dB, which is 5.8 times of that (8 dB) for rGO/FeNi/epoxy composites with the same rGO/FeNi mass fraction. At the same time, the rGH@FeNi/epoxy composites also possess excellent thermal stability (heat-resistance index and temperature at the maximum decomposition rate are 179.1 and 389.0 °C respectively) and mechanical properties (storage modulus is 8296.2 MPa).

The N−N atropisomer, as an important and intriguing chiral system, was widely present in natural products, pharmaceutical lead compounds, and advanced material skeletons. The anisotropic structural characteristics caused by its special axial rotation have always been one of the challenges that chemists strive to overcome. Herein, we report an efficient method for the enantioselective synthesis of N−N axially chiral frameworks via a cobalt-catalyzed atroposelective C-H activation/annulation process. The reaction proceeds under mild conditions by using Co(OAc) 2 ·4H 2 O as the catalyst with a chiral salicyl-oxazoline (Salox) ligand and O 2 as an oxidant, affording a variety of N−N axially chiral products with high yields and enantioselectivities. This protocol provides an efficient approach for the facile construction of N−N atropisomers and further expands the range of of N−N axially chiral derivatives. Additionally, under the conditions of electrocatalysis, the desired N−N axially chiral products were also successfully achieved with good to excellent efficiencies and enantioselectivities. Atropisomers are an important chiral system which are widely present in natural products but atropisomerism bearing a N−N bond remains largely underdeveloped. Here, the authors report an efficient method for the enantioselective synthesis of N−N axially chiral frameworks under mild conditions via a cobalt-catalyzed atroposelective C-H activation/annulation

In the literature on optimal portfolio selection problems, it is rare that closed-form solutions are found. It is even more so when liquidity risk needs to be taken into consideration. In this paper, we present a closed-form solution for the optimal weights of a portfolio that consists of a risky and riskless asset under a new key assumption that the liquidity risk is directly proportional to the wealth of the portfolio invested in the risky asset. The solution found is for the Constant Relative Risk Aversion (CRRA) utility function, after successfully solving the associated HJB (HamiltonJacobi-Bellman) equation exactly. Due to the presence of liquidity risk, the research findings reveal that the optimal weights are consistently lower than those found by [19]. Finally, the quantitative impact of the proposed solution is discussed.

Bismuth (Bi) has been known as a highly efficient electrocatalyst for CO 2 reduction reaction. Stable free-standing two-dimensional Bi monolayer (Bismuthene) structures have been predicted theoretically, but never realized experimentally. Here, we show the first simple large-scale synthesis of free-standing Bismuthene, to our knowledge, and demonstrate its high electrocatalytic efficiency for formate (HCOO − ) formation from CO 2 reduction reaction. The catalytic performance is evident by the high Faradaic efficiency (99% at −580 mV vs. Reversible Hydrogen Electrode (RHE)), small onset overpotential (<90 mV) and high durability (no performance decay after 75 h and annealing at 400 °C). Density functional theory calculations show the structure-sensitivity of the CO 2 reduction reaction over Bismuthene and thicker nanosheets, suggesting that selective formation of HCOO − indeed can proceed easily on Bismuthene (111) facet due to the unique compressive strain. This work paves the way for the extensive experimental investigation of Bismuthene in many different fields. Stable free-standing two-dimensional Bi monolayer (Bismuthene) structures have been predicted theoretically, but never realized experimentally. Here, the authors show a large-scale synthesis of free-standing Bismuthene and its electrocatalytic activity for CO 2 reduction to formate.

Introduction Kynurenine (KYN) accumulation in periphery induces brain injury, responsible for depression. α‐Asarone is a simple phenylpropanoids that exerts beneficial effects on central nervous system. However, the effect of α‐asarone on periphery is unexplored. Aims Here, we investigated its protective role against depression from the aspect of KYN metabolism in skeletal muscle. Methods The antidepressant effects of α‐asarone were evaluated in chronic mild stress (CMS) and muscle‐specific PGC‐1α‐deficient mice. The effects of KYN metabolism were determined in mice and C2C12 myoblasts. Results α‐Asarone exerted antidepressant effects in CMS and KYN‐challenged mice via modulating KYN metabolism. In myoblasts, α‐asarone regulated PGC‐1α induction via cAMP/CREB signaling and upregulated KYN aminotransferases (KATs) to increase KYN clearance in a manner dependent on PGC‐1α. KAT function is coupled with malate–aspartate shuttle (MAS), while α‐asarone combated oxidative stress to protect MAS and mitochondrial integrity by raising the NAD+/NADH ratio, ensuring effective KYN disposal. In support, the antidepressant effect of α‐asarone was diminished by muscle‐specific PGC‐1α deficient mice subjected to KYN challenge. Conclusion KATs coupled with MAS to clear KYN in muscle. α‐Asarone increased PGC‐1α induction and promoted KYN disposal in muscle, suggesting that protection of mitochondria is a way for pharmacological intervention to depression. α‐Asarone modulates PGC‐1α induction via cAMP/CREB signaling and combats oxidative stress to protect MAS and mitochondrial integrity by raising the NAD+/NADH ratio to improve KAT/MAS integration, and thereby facilitating KYN clearance in muscle and mediating resilience to depression.

The simultaneous construction of multiple stereogenic elements in a single step is highly appealing and desirable in the field of asymmetric synthesis. Furthermore, the catalytic enantioselective synthesis of inherently chiral calix[n]arenes with high enantiopurity has long been a challenging endeavor. Herein, we report an enantioselective cobalt-catalyzed C–H activation/annulation for the efficient construction of inherently chiral calix[4]arenes bearing multiple C–N axially chiral element. By employing the benzamide tethered calix[4]arene as the substrate, the C–H annulation with alkynes can be successfully accomplished, leading to the generation of multiple stereogenic elements. A wide range of calix[4]arenes and alkynes are found to be well compatible, and exhibit good yields, high enantioselectivity and excellent diastereoselectivity. Notably, the gram-scale reaction, catalytic application, synthetic transformations, and chiral recognition further showcase the potential applications of this protocol. The catalytic enantioselective synthesis of inherently chiral calix[n]arenes with high enantiopurity has long been a challenging endeavor. Herein, the authors report an enantioselective cobalt-catalyzed C–H activation/annulation for the efficient construction of inherently chiral calix[4]arenes bearing multiple C–N axially chiral element.

Kynurenine pathway (KP) is the primary path of tryptophan (Trp) catabolism in most mammalian cells. The KP generates several bioactive catabolites, such as kynurenine (Kyn), kynurenic acid (KA), 3-hydroxykynurenine (3-HK), xanthurenic acid (XA), and 3-hydroxyanthranilic acid (3-HAA). Increased catabolite concentrations in serum are associated with several cardiovascular diseases (CVD), including heart disease, atherosclerosis, and endothelial dysfunction, as well as their risk factors, including hypertension, diabetes, obesity, and aging. The first catabolic step in KP is primarily controlled by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). Following this first step, the KP has two major branches, one branch is mediated by kynurenine 3-monooxygenase (KMO) and kynureninase (KYNU) and is responsible for the formation of 3-HK, 3-HAA, and quinolinic acid (QA); and another branch is controlled by kynurenine amino-transferase (KAT), which generates KA. Uncontrolled Trp catabolism has been demonstrated in distinct CVD, thus, understanding the underlying mechanisms by which regulates KP enzyme expression and activity is paramount. This review highlights the recent advances on the effect of KP enzyme expression and activity in different tissues on the pathological mechanisms of specific CVD, KP is an inflammatory sensor and modulator in the cardiovascular system, and KP catabolites act as the potential biomarkers for CVD initiation and progression. Moreover, the biochemical features of critical KP enzymes and principles of enzyme inhibitor development are briefly summarized, as well as the therapeutic potential of KP enzyme inhibitors against CVD is briefly discussed.